Experimental drug AMG 420 tested in Tough-to-Treat myeloma – early trial halted
NCT ID NCT03836053
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested a drug called AMG 420 in 23 people with multiple myeloma that had returned or stopped responding to at least three prior treatments. Participants received the drug as a continuous 28-day IV infusion. The study aimed to find the safest dose and check for side effects, but it was terminated early. Results may help guide future research, but no conclusions about effectiveness can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AMG 420
- What this could lead to
- If successful, this could point toward a new treatment option for patients with multiple myeloma that has stopped responding to other therapies.
- What could go wrong
- This was a very early Phase 1 trial with only 23 participants, and it was terminated early. The drug may cause serious side effects like cytokine release syndrome, and it is unknown if it will work in larger groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Advocate Lutheran General Hospital
Park Ridge, Illinois, 60068, United States
-
Centre Hospitalier Universitaire Dinant Godinne - Universite Catholique de Louvain Namur
Yvoir, 5530, Belgium
-
Centres Hospitaliers Jolimont - Hopital de Jolimont
Haine Saint Paul - La Louviere, 7100, Belgium
-
Kantonsspital St Gallen
Sankt Gallen, 9007, Switzerland
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
-
National Hospital Organization Okayama Medical Center
Okayama, Okayama-ken, 701-1192, Japan
-
St Vincents Hospital Melbourne
Fitzroy, VIC, Victoria, 3065, Australia
-
St Vincents Hospital Sydney
Darlinghurst, New South Wales, 2010, Australia
-
Wake Forest Baptist Health
Winston-Salem, North Carolina, 27157, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.